BONFANTI PAOLO

Giurco, M., Taramasso, L., Ricci, E., Squillace, N., Ferrara, S., Parisini, A., et al. (2026). Tolerability and Virologic Outcomes after Transition from Long-Acting Injectable ART to Oral ART. AIDS PATIENT CARE AND STDS [10.1177/10872914261487462]. Dettaglio

Calcagno, A., Candela, C., Riva, A., Calza, S., Fioretti, B., Gardini, S., et al. (2026). Bimonthly Administered Long-Acting Cabotegravir and Rilpivirine Are Highly Effective and Well-Tolerated in People With Human Immunodeficiency Virus Above 65 Years. OPEN FORUM INFECTIOUS DISEASES, 13(1) [10.1093/ofid/ofaf817]. Dettaglio

Giurco, M., Taramasso, L., Ricci, E., Squillace, N., Ferrara, S., Parisini, A., et al. (2026). SC22 Life after long-acting therapy: what happens when CAB/RPV is discontinued?. In Abstracts from the 18th Italian Conference on AIDS and Antiviral Research (pp.91-92) [10.1136/sextrans-icar-2026.89]. Dettaglio

Vergori, A., Cervo, A., Roen, A., Gagliardini, R., Clemente, T., Mazzotta, V., et al. (2026). Risk of Developing Low-Level Viral Rebound Among People With HIV Receiving 2- or 3-Drug Regimens: A Case-Control Study Nested in the ICONA Cohort. OPEN FORUM INFECTIOUS DISEASES, 13(5) [10.1093/ofid/ofag250]. Dettaglio

Mezzadri, L., Bonfanti, P. (2026). When Faster Diagnosis Is Not Enough: Bringing Diagnostic Stewardship into Antimicrobial Stewardship. LE INFEZIONI IN MEDICINA, 34(2), 123-125 [10.53854/liim-3402-1]. Dettaglio